Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 2/2012

01-02-2012 | Original paper

Does hormone replacement therapy and use of oral contraceptives increase the risk of non-melanoma skin cancer?

Authors: Fatima Birch-Johansen, Allan Jensen, Anne Braae Olesen, Jane Christensen, Anne Tjønneland, Susanne K. Kjær

Published in: Cancer Causes & Control | Issue 2/2012

Login to get access

Abstract

Objective

We aimed to examine whether use of hormone replacement therapy (HRT) and oral contraceptives (OC) affect the risk of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) in women.

Methods

Using data from 29,875 women enrolled in the prospective “Diet, Cancer, and Health” study between 1993 and 1997, women with available information on HRT and OC use at baseline were identified. Statistical analyses were based on the Cox’s proportional hazards model.

Results

The mean age at enrollment in the study was 56.7 years, whereas the mean age at the end of follow-up was 67.5 years. 1,175 cases of BCC and 76 cases of SCC were identified in the cohort during follow-up through 2007. The BCC incidence rate ratio was 1.15 (95% CI: 1.07–1.37) for ever users of HRT at baseline compared to never users, whereas risk of BCC was unaffected by duration of HRT use. Ever use of HRT was not associated with SCC risk but a significantly increased risk of 1.35 (95% CI: 1.05–1.72) associated with every 5 years of HRT use was observed. No convincing associations between OC use and BCC or SCC risk were observed.

Conclusion

The findings indicated that HRT but not OC may increase the risk of NMSC. However, further studies are warranted as risk estimates for SCC had relatively low precision due to a limited number of SCC cases.
Literature
1.
Brewster DH, Bhatti LA, Inglis JH, Nairn ER, Doherty VR (2007) Recent trends in incidence of nonmelanoma skin cancers in the East of Scotland, 1992–2003. Br J Dermatol 156:1295–1300PubMedCrossRef
2.
de VE, Louwman M, Bastiaens M, de GF, Coebergh JW (2004) Rapid and continuous increases in incidence rates of basal cell carcinoma in the southeast Netherlands since 1973. J Invest Dermatol 123:634–638CrossRef
3.
4.
5.
Birch-Johansen F, Jensen A, Mortensen L, Olesen AB, Kjaer SK (2010) Trends in the incidence of nonmelanoma skin cancer in Denmark 1978–2007: rapid incidence increase among young Danish women. Int J Cancer 127:2190–2198PubMedCrossRef
6.
Harris RB, Griffith K, Moon TE (2001) Trends in the incidence of nonmelanoma skin cancers in southeastern Arizona, 1985–1996. J Am Acad Dermatol 45:528–536PubMedCrossRef
7.
Hayes RC, Leonfellner S, Pilgrim W, Liu J, Keeling DN (2007) Incidence of nonmelanoma skin cancer in New Brunswick, Canada, 1992 to 2001. J Cutan Med Surg 11:45–52PubMed
8.
Bath-Hextall F, Leonardi-Bee J, Smith C, Meal A, Hubbard R (2007) Trends in incidence of skin basal cell carcinoma. Additional evidence from a UK primary care database study. Int J Cancer 121:2105–2108PubMedCrossRef
9.
Karagas MR, Greenberg ER, Spencer SK, Stukel TA, Mott LA (1999) Increase in incidence rates of basal cell and squamous cell skin cancer in New Hampshire, USA. New Hampshire Skin Cancer Study Group. Int J Cancer 81:555–559PubMedCrossRef
10.
Bielsa I, Soria X, Esteve M, Ferrandiz C (2009) Population-based incidence of basal cell carcinoma in a Spanish Mediterranean area. Br J Dermatol 161:1341–1346PubMedCrossRef
11.
Christenson LJ, Borrowman TA, Vachon CM et al (2005) Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA 294:681–690PubMedCrossRef
12.
Young C (2009) Solar ultraviolet radiation and skin cancer. Occup Med (Lond) 59:82–88CrossRef
13.
Koster B, Thorgaard C, Clemmensen IH, Philip A (2009) Sunbed use in the Danish population in 2007: a cross-sectional study. Prev Med 48:288–290PubMedCrossRef
14.
Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD (2002) Postmenopausal hormone replacement therapy: scientific review. JAMA 288:872–881PubMedCrossRef
15.
Casey PM, Cerhan JR, Pruthi S (2008) Oral contraceptive use and risk of breast cancer. Mayo Clin Proc 83:86–90PubMedCrossRef
16.
La VC (2006) Oral contraceptives and ovarian cancer: an update, 1998–2004. Eur J Cancer Prev 15:117–124CrossRef
17.
Lens M, Bataille V (2008) Melanoma in relation to reproductive and hormonal factors in women: current review on controversial issues. Cancer Causes Control 19:437–442PubMedCrossRef
18.
Mackie RM, Hauschild A, Eggermont AM (2009) Epidemiology of invasive cutaneous melanoma. Ann Oncol 20:vi1–vi7PubMedCrossRef
19.
Gupta A, Driscoll MS (2010) Do hormones influence melanoma? Facts and controversies. Clin Dermatol 28:287–292PubMedCrossRef
20.
Grossman L, Wei Q (1995) DNA repair and epidemiology of basal cell carcinoma. Clin Chem 41:1854–1863PubMed
21.
Welsh MM, Karagas MR, Applebaum KM, Spencer SK, Perry AE, Nelson HH (2008) A role for ultraviolet radiation immunosuppression in non-melanoma skin cancer as evidenced by gene-environment interactions. Carcinogenesis 29:1950–1954PubMedCrossRef
22.
Asgari MM, Efird JT, Warton EM, Friedman GD (2010) Potential risk factors for cutaneous squamous cell carcinoma include oral contraceptives: results of a nested case-control study. Int J Environ Res Public Health 7:427–442PubMedCrossRef
23.
Applebaum KM, Nelson HH, Zens MS, Stukel TA, Spencer SK, Karagas MR (2009) Oral contraceptives: a risk factor for squamous cell carcinoma? J Invest Dermatol 129:2760–2765PubMedCrossRef
24.
Vessey MP, Painter R, Powell J (2000) Skin disorders in relation to oral contraception and other factors, including age, social class, smoking and body mass index. Findings in a large cohort study. Br J Dermatol 143:815–820PubMedCrossRef
25.
Wei Q, Matanoski GM, Farmer ER, Hedayati MA, Grossman L (1994) DNA repair related to multiple skin cancers and drug use. Cancer Res 54:437–440PubMed
26.
Tjonneland A, Overvad K, Haraldsdottir J, Bang S, Ewertz M, Jensen OM (1991) Validation of a semiquantitative food frequency questionnaire developed in Denmark. Int J Epidemiol 20:906–912PubMedCrossRef
27.
Overvad K, Tjonneland A, Haraldsdottir J, Ewertz M, Jensen OM (1991) Development of a semiquantitative food frequency questionnaire to assess food, energy and nutrient intake in Denmark. Int J Epidemiol 20:900–905PubMedCrossRef
28.
29.
30.
Lamberg AL, Cronin-Fenton D, Olesen AB (2010) Registration in the Danish regional nonmelanoma skin cancer dermatology database: completeness of registration and accuracy of key variables. Clin Epidemiol 2:123–136PubMed
31.
Greenland S (1995) Dose-response and trend analysis in epidemiology: alternatives to categorical analysis. Epidemiology 6:356–365PubMedCrossRef
32.
Fung TT, Hunter DJ, Spiegelman D, Colditz GA, Rimm EB, Willet WC (2002) Intake of alcohol and alcoholic beverages and the risk of basal cell carcinoma of the skin. Cancer Epidemiol Biomarkers Prev 11:1119–1122PubMed
33.
Freedman DM, Sigurdson A, Doody MM, Mabuchi K, Linet MS (2003) Risk of basal cell carcinoma in relation to alcohol intake and smoking. Cancer Epidemiol Biomarkers Prev 12:1540–1543PubMed
34.
McLoone NM, Middleton RJ, Gavin AT, Walsh M, Dolan OM (2003) Audit of basal cell carcinoma: registration practice. Br J Dermatol 148:371PubMedCrossRef
35.
Cooper SM, George S (2001) Photosensitivity reaction associated with use of the combined oral contraceptive. Br J Dermatol 144:641–642PubMedCrossRef
36.
Silver EA, Silver AH, Silver DS, McCalmont TH (2003) Pseudoporphyria induced by oral contraceptive pills. Arch Dermatol 139:227–228PubMedCrossRef
37.
Sedee A, van Beijersbergen HG (1985) Photosensitized decomposition of contraceptive steroids: a possible explanation for the observed (photo)allergy of the oral contraceptive pill. Arch Pharm (Weinheim) 318:111–119CrossRef
38.
Wei Q, Matanoski GM, Farmer ER, Hedayati MA, Grossman L (1994) DNA repair and susceptibility to basal cell carcinoma: a case-control study. Am J Epidemiol 140:598–607PubMed
39.
40.
Thiele JJ, Gilchrest BA (2008) Aging skin. In: Nouri K (ed) Skin cancer. McGraw-Hill Professional, New York, NY pp 17–31
41.
Munoz N, Castellsague X, de Gonzalez AB, Gissmann L (2006) Chapter 1: HPV in the etiology of human cancer. Vaccine 24:1–10CrossRef
42.
Nindl I, Gottschling M, Stockfleth E (2007) Human papillomaviruses and non-melanoma skin cancer: basic virology and clinical manifestations. Dis Markers 23:247–259PubMed
43.
Armstrong BK, Kricker A (2001) The epidemiology of UV induced skin cancer. J Photochem Photobiol B 63:8–18PubMedCrossRef
44.
Lock-Andersen J, Drzewiecki KT, Wulf HC (1999) Naevi as a risk factor for basal cell carcinoma in Caucasians: a Danish case-control study. Acta Derm Venereol 79:314–319PubMedCrossRef
Metadata
Title
Does hormone replacement therapy and use of oral contraceptives increase the risk of non-melanoma skin cancer?
Authors
Fatima Birch-Johansen
Allan Jensen
Anne Braae Olesen
Jane Christensen
Anne Tjønneland
Susanne K. Kjær
Publication date
01-02-2012
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 2/2012
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-011-9887-4

Other articles of this Issue 2/2012

Cancer Causes & Control 2/2012 Go to the issue

Original paper

Shrinking, widening, reversing, and stagnating trends in US socioeconomic inequities in cancer mortality for the total, black, and white populations: 1960–2006

Original paper

Serum insulin-like growth factors and mortality in localised and advanced clinically detected prostate cancer

Review article

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: a systematic review

Original paper

Case–control study of smoking and non-melanoma skin cancer

Original paper

What factors affect the odds of NSW cancer patients presenting with localised as opposed to more advanced cancer?

Original paper

Associations of birth weight and physical activity with sex steroids in preschool Japanese children
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits